在局部骨肉瘤中新辅助MAP化疗的药理学:基于GEIS-33协议数据的研究
Juliana Salazar1, María J Arranz2, Javier Martin-Broto3
1Translational Medical Oncology Laboratory, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.
Pharmaceutics
|January 8, 2025
概括
基因修复和药物代谢基因中的遗传变异可以预测骨髓瘤患者对甲基酸盐,多克索鲁比和西斯类化学疗法的反应. 这些生物标志物可能有助于个性化治疗,并减少局部骨髓瘤的毒性.
科学领域:
- 在瘤学瘤学.
- 药物基因组学 药物基因组学
- 分子生物学分子生物学
背景情况:
- 骨髓瘤是最常见的原发性恶性骨瘤.
- 目前的治疗包括甲状腺素,多克索鲁比辛和西斯 (MAP) 化疗,手术和辅助疗法.
- 对化疗的病理反应是关键的预后因素,但缺乏分子预测因素.
研究的目的:
- 研究DNA修复和药物代谢基因中的生殖系遗传变异,作为骨髓瘤中MAP化疗反应的预测因子.
- 确定用于预测病理反应和化疗诱导毒性的生物标志物.
主要方法:
- 在69位局部骨髓瘤患者中,对8个基因 (MTHFR,SLC19A1,ABCB1,ABCC2,ABCC3,ERCC1,ERCC2,GSTP1) 的生殖线多态基因定型.
- 在瘤组织中分析p-glycoprotein表达.
- 关联研究将遗传变异和蛋白质表达与病理反应和甲醇甲酸诱导的肝毒性相关联.
主要成果:
- ABCC2 rs2273697和ERCC2 rs1799793变异与MAP化疗病理反应不佳显著相关.
- ABCB1 rs1128503和ABCC3 rs4793665变种与甲基酸诱导的3-4级肝毒性有关.
- P-糖蛋白表达与病理反应没有相关性.
结论:
- 在ABC载体和DNA修复基因中的遗传变异显示出在骨髓瘤中对MAP化疗反应的预测生物标志物的潜力.
- 这些发现支持开发个性化治疗策略,以改善治疗结果并最大限度地减少毒性.
- 需要进一步的研究来验证这些生物标志物在更大的队列中是否有效.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...